"Genes, BRCA2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tumor suppressor gene (GENES, TUMOR SUPPRESSOR) located on human chromosome 13 at locus 13q12.3. Mutations in this gene predispose humans to breast and ovarian cancer. It encodes a large, nuclear protein that is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev 2000;14(11):1400-6)
| Descriptor ID |
D024522
|
| MeSH Number(s) |
G05.360.340.024.340.375.249.105 G05.360.340.024.340.415.400.105
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Genes, BRCA2".
Below are MeSH descriptors whose meaning is more specific than "Genes, BRCA2".
This graph shows the total number of publications written about "Genes, BRCA2" by people in this website by year, and whether "Genes, BRCA2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 2 | 0 | 2 |
| 2002 | 4 | 0 | 4 |
| 2003 | 2 | 1 | 3 |
| 2004 | 3 | 0 | 3 |
| 2005 | 7 | 0 | 7 |
| 2006 | 4 | 4 | 8 |
| 2007 | 3 | 1 | 4 |
| 2008 | 7 | 1 | 8 |
| 2009 | 3 | 1 | 4 |
| 2010 | 3 | 0 | 3 |
| 2011 | 4 | 1 | 5 |
| 2012 | 4 | 3 | 7 |
| 2013 | 1 | 0 | 1 |
| 2014 | 6 | 2 | 8 |
| 2015 | 2 | 3 | 5 |
| 2016 | 5 | 2 | 7 |
| 2017 | 3 | 0 | 3 |
| 2018 | 2 | 2 | 4 |
| 2019 | 3 | 3 | 6 |
| 2021 | 1 | 3 | 4 |
| 2022 | 1 | 4 | 5 |
| 2023 | 0 | 4 | 4 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Genes, BRCA2" by people in Profiles.
-
Myeloid neoplasms in individuals with breast and ovarian cancer and the association with deleterious germline variants. Gynecol Oncol. 2024 08; 187:235-240.
-
Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a BRCA1 or BRCA2 Mutation. Cancer Res Commun. 2023 11 28; 3(11):2420-2429.
-
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study. Eur Urol. 2023 09; 84(3):321-330.
-
The association between age at breast cancer diagnosis and prevalence of pathogenic variants. Breast Cancer Res Treat. 2023 Jun; 199(3):617-626.
-
Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. J Clin Oncol. 2023 03 20; 41(9):1703-1713.
-
The risks of cancer in older women with BRCA pathogenic variants: How far have we come? Cancer. 2023 03 15; 129(6):901-907.
-
Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay. Clin Cancer Res. 2022 09 01; 28(17):3742-3751.
-
Comparison of Outcomes Between BRCA Pathogenic Variant Carriers Undergoing Breast-Conserving Surgery Versus Mastectomy. Ann Surg Oncol. 2022 Aug; 29(8):4706-4713.
-
Mutational spectrum of breast cancer susceptibility genes among women ascertained in a cancer risk clinic in Northeast Brazil. Breast Cancer Res Treat. 2022 Jun; 193(2):485-494.
-
Detection of germline variants in Brazilian breast cancer patients using multigene panel testing. Sci Rep. 2022 03 09; 12(1):4190.